GlobeNewswire Inc | Sep 3, 2020 08:00AM EDT

September 03, 2020

NEWTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in fireside chats at two investor conferences in September:

Baird 2020 Global Healthcare Conference Date: Thursday, September 10Time: 9:40 a.m. ET

H.C. Wainwright & Co. 22nd Annual Global Investor Conference Date: Tuesday, September 15Time: 12:30 p.m. ET

Live audio webcasts of the presentations will be available under Events and Presentations in the Investors section of the Companys website atwww.allenapharma.com. Replays of the webcasts will be available on the Allena website for 30 days following each presentation.

About Allena Pharmaceuticals Allena Pharmaceuticals, Inc.is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allenas lead product candidate, reloxaliase, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Investor Contact Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200hannah.deresiewicz@sternir.com

Media Contact Adam Daley Berry & Company Public Relations 212-253-8881adaley@berrypr.com